PPAR‐α and ‐γ but not ‐δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF‐κ B‐independent effect
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator‐activated receptors (PPARs) are ligand‐activated transcription factors that have been proposed to regulate inflammation by antagonising the nuclear factor‐κ B (NF‐κ B) signalling pathway. We investigated the role of PPARs using synthetic agonists in murine models of airway inflammation, and addressed the possible effect on NF‐κ B signalling in vitro using a human epithelial cell line, A549. Sensitised BALB/c mice exposed to an aerosol solution of ovalbumin had an increased number of airway eosinophils, neutrophils and lymphocytes. When given intranasally an hour before the aerosol challenge, a PPAR‐α (GW 9578) and PPAR‐γ (GI 262570) selective agonist as well as a dual PPAR‐α/γ (GW 2331) agonist selectively inhibited allergen‐induced bronchoalveolar lavage eosinophil and lymphocyte but not neutrophil influx. In contrast, a PPAR‐δ agonist (GW 501516) was inactive. When given intranasally an hour before challenge, PPAR‐α and PPAR‐γ selective agonists as well as a dual PPAR‐α/γ agonist did not inhibit lipopolysaccharide‐induced bronchoalveolar lavage neutrophil influx or tumour necrosis factor‐α (TNF‐α) and KC production. In A549 cells, selective agonists for PPAR‐α, ‐γ and ‐δ did not inhibit intracellular adhesion molecule‐1 expression following stimulation with proinflammatory cytokines. In addition, IL‐8 release and the activation of an NF‐κ B‐responsive reporter gene construct were inhibited only at micromolar concentrations, suggesting that these effects were not PPAR‐mediated. Our in vivo data show that agonists of PPAR‐α and ‐γ, but not ‐δ, inhibit allergen‐induced bronchoalveolar lavage eosinophil and lymphocyte influx. In vitro data suggest that this effect might not be mediated by antagonism of the NF‐κ B pathway. British Journal of Pharmacology (2003) 139, 163–171. doi:10.1038/sj.bjp.0705232
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345 · cited 1×
“In vivo, inflammation induced by LTB4, a PPAR-a ligand, was shown to be prolonged in PPAR-a-deficient mice (Devchand et al., 1996), suggesting an anti-inflammatory role for this receptor.”
BackgroundDelerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 2×
“…murine macrophage activation in vitro (Ricote et al., 1998), the ligands used have been shown to have anti-inflammatory effects when using PPAR-g-deficient macrophages (Chawla et al., 2001), indicating that these compounds do not require PPAR-g for their anti-inflammatory effects in macrophages.”
BackgroundPeroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 2×
“It has been suggested that PPAR activators exert their antiinflammatory effects by antagonising the NF-kB pathway (Delerive et al., 2001).”
BackgroundMethodThe role of PPARs in inflammation and immunity
Clark, R. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.388 · Cited by 337 · cited 2×
“So far, in vitro and in vivo data have led to contradictory results, probably because of the use of nonspecific ligands or the use of specific ligands at concentrations far exceeding those required to bind to the receptors (Clark, 2002).”
BackgroundResult
Cited by
PPARγ as a new therapeutic target in inflammatory bowel diseases
Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., Chavatte, P., Chamaillard, M., & Desreumaux, P. (2006) · Gut · doi:10.1136/gut.2006.093484 · Cited by 450
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
DeWitt, J. C., Shnyra, A., Badr, M. Z., Loveless, S. E., Hoban, D., Frame, S. R., Cunard, R., Anderson, S. E., Meade, B. J., Peden-Adams, M. M., et al. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440802209804 · Cited by 266
The impact of diet on asthma and allergic diseases
Julia, V., Macia, L., & Dombrowicz, D. (2015) · Nature Reviews Immunology · doi:10.1038/nri3830 · Cited by 253
Necela, B. M., Su, W., & Thompson, E. A. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02849.x · Cited by 140
Metadata
- Authors
- Trifilieff, A., Bench, A., Hanley, M., Bayley, D., Campbell, E., & Whittaker, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2003-05
- Volume
- 139
- Issue
- 1
- Pages
- 163-171
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2000498772
- Cited by
- 148
- References
- 9
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.